Skip to main content

Market Overview

Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

Share:

On Wednesday, Sterne Agee initiated coverage on shares of Teva Pharmaceutical Industries (NYSE: TEVA) with a Neutral rating and $53 price target.

Analyst Shibani Malhotra believes “strong conversion of Copaxone 20mg/ml to its 40mg/ml formulation is crucial.”

The analyst credits the stocks year-to-date outperformance (up 25 percent) to the company “signaling its willingness to consider a ‘transformational deal.'”

Shibani would prefer “to see management focus on execution of its realignment and cost-cutting strategy before embarking on any ambitious M&A.”

The stock is up one percent to $50.10 in Wednesday's trading.

Latest Ratings for TEVA

DateFirmActionFromTo
Feb 2022BarclaysMaintainsEqual-Weight
Jan 2022Argus ResearchDowngradesBuyHold
Oct 2021Raymond JamesDowngradesOutperformMarket Perform

View More Analyst Ratings for TEVA

View the Latest Analyst Ratings

 

Related Articles (TEVA)

View Comments and Join the Discussion!

Posted-In: Shibani Malhotra Sterne AgeeAnalyst Color Analyst Ratings

Latest Ratings

StockFirmActionPT
SEDGB of A SecuritiesMaintains411.0
PTLOPiper SandlerMaintains28.0
AOUTLake StreetMaintains26.0
RAPTPiper SandlerMaintains52.0
OCXLake StreetMaintains6.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com